KRAS and neoplasm: Sequencing revealed a tumor mutational burden of 3.0 mutations/megabase, a pathogenic KRAS p.G12D variant, amplification of ERBB2, and copy number loss of CDKN2A and RB1. Microsatellite instability was not detected.